Changeflow GovPing Pharma & Drug Safety EPO Patent: Selective Regulatory Gene System fo...
Routine Notice Added Final

EPO Patent: Selective Regulatory Gene System for Genetically Modified Immune Cell Therapy

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4502162A1 concerning a Selective Regulatory Gene (SRG) System for Genetically Modified Immune Cell Therapy. The patent application lists Jichi Medical University and Takara Bio Inc. as applicants.

What changed

The European Patent Office (EPO) has published patent application EP4502162A1, titled 'Selective Regulatory Gene (SRG) System for Genetically Modified Immune Cell Therapy'. This application, filed by Jichi Medical University and Takara Bio Inc., details a novel system for controlling gene expression in genetically modified immune cells, potentially impacting the development and application of advanced cell therapies.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on entities. However, companies involved in the development of cell therapies, particularly those utilizing genetic modification techniques, should be aware of this patent as it may affect intellectual property landscapes and future research and development strategies in the field of immunotherapy.

Source document (simplified)

← EPO Patent Bulletin

SELECTIVE REGULATORY GENE (SRG) SYSTEM FOR GENETICALLY MODIFIED IMMUNE CELL THERAPY

Publication EP4502162A1 Kind: A1 Mar 18, 2026

Applicants

Jichi Medical University, Takara Bio Inc.

Inventors

UCHIBORI, Ryosuke, OHMINE, Ken, OZAWA, Keiya

IPC Classifications

C12N 15/62 20060101AFI20260210BHEP A61K 35/12 20150101ALI20260210BHEP A61P 35/00 20060101ALI20260210BHEP C07K 14/715 20060101ALI20260210BHEP C07K 19/00 20060101ALI20260210BHEP C12N 5/0783 20100101ALI20260210BHEP C12N 5/10 20060101ALI20260210BHEP C12N 15/12 20060101ALI20260210BHEP C12N 15/63 20060101ALI20260210BHEP A61K 40/31 20250101ALI20260210BHEP A61K 40/42 20250101ALI20260210BHEP C07K 14/71 20060101ALI20260210BHEP A61K 40/11 20250101ALI20260210BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

SELECTIVE REGULATORY GENE (SRG) SYSTEM FOR GENETICALLY MODIFIED IMMUNE CELL THERAPY

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4502162A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Cell Therapy Development Gene Therapy
Geographic scope
European Union EU

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Biotechnology Medical Devices

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.